Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Bone Marrow Transplantation in Treating Patients With Acute Leukemia in First or Second Remission
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002534
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Conditions
- Interventions
- Biological: filgrastimDrug: carboplatinDrug: cyclophosphamideDrug: carmustineDrug: doxorubicin hydrochlorideDrug: cisplatinDrug: tamoxifen citrateRadiation: radiation therapyDrug: paclitaxelDrug: thiotepaProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 602
- Registration Number
- NCT00002772
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer
- Conditions
- First Posted Date
- 2004-04-14
- Last Posted Date
- 2010-09-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00003080
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2004-04-13
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Herbert Irving Comprehensive Cancer Center
- Registration Number
- NCT00012311
- Locations
- 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2012-10-26
- Target Recruit Count
- 209
- Registration Number
- NCT00005798
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Halifax Medical Center, Daytona Beach, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1
- Registration Number
- NCT00078988
- Locations
- 🇺🇸
Children's Hospital and Health Center - San Diego, San Diego, California, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Registration Number
- NCT00006123
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-02-09
- Last Posted Date
- 2020-07-14
- Target Recruit Count
- 12
- Registration Number
- NCT00003086
- Locations
- 🇺🇸
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
- Conditions
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 45
- Registration Number
- NCT00003852
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, France
🇫🇷Centre Leon Berard, Lyon, France
Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2018-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 184
- Registration Number
- NCT00002836
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.